ASTERDM Price ActionAster DM Healthcare is trading around ₹632–₹634 as of September 4, 2025, and has shown solid resilience and upward movement over recent sessions. The company’s market capitalization stands at about ₹32,122 crore, and its current price-to-book ratio is roughly 9.4, reflecting growth expectations and sector strength.
Recent financial results highlight substantial improvement: Q1 FY26 revenue reached ₹1,078 crore, up 8% year-on-year, and consolidated net profit for the quarter is ₹85.52 crore, maintaining momentum following last year’s major gains from the strategic disposal of its Gulf business. The EBITDA margin for FY25 has strengthened, averaging 19.5%, due to increased patient volumes and operational efficiency. For the whole of FY25, revenue grew 12% to ₹4,138 crore, and net profit posted a strong jump to over ₹5,400 crore with strategic gains from the GCC business separation.
Balance sheet analysis shows rising book value and a stable asset base, indicating ongoing capital investment and sector expansion. Total expenses have grown moderately, while EBIT and PAT both reflect favorable YoY growth, with EBIT up 30% for the recent period. Trading volumes are steady, and the price action is currently above key moving averages, supporting a bullish technical outlook.
Aster DM Healthcare’s positive trend is backed by solid quarterly results, sector tailwinds, and strategic realignment of its international operations. Investors remain optimistic for further medium-term gains if the company sustains improved margins and expanding patient demographics.
